Diagnostic methods for determining prognosis of non-small cell lung cancer

US9297045B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Dimitri Semizarov · Chicago, US
• Xin Lu · Cambridge, US
• Ke Zhang · San Clemente, US
• Rick R. Lesniewski · Collegeville, US
• John Coon · Oak Park, US

Key dates

• Filing date: Oct 25, 2010
• Grant date: Mar 29, 2016
• Expiry date: Oct 25, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus.